Management of systemic lupus erythematosus in Chinese patients

Expert Review of Clinical Immunology

Volumn 3, Issue 6, 2007, Pages 925-935

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Chinese; Morbidity; Nephritis; Novel; Strategy; Therapy; Trreatment

Indexed keywords

ABATACEPT; ABETIMUS; ANTIHISTAMINIC AGENT; AUTOANTIBODY; AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA; EPRATUZUMAB; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; LEFLUNOMIDE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; OCRELIZUMAB; PARACETAMOL; PLACEBO; PNEUMOCOCCUS VACCINE; PRASTERONE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; AFRICAN AMERICAN; AFRICAN CARIBBEAN; ALOPECIA; AMENORRHEA; ASIA; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD DISEASE; BODY MASS; BONE MARROW SUPPRESSION; CAUCASIAN; CHINESE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EARLY MENOPAUSE; ENVIRONMENTAL FACTOR; ETHNICITY; EXERCISE; FRAGILITY FRACTURE; GENERAL CONDITION IMPROVEMENT; GENETIC SUSCEPTIBILITY; GINGIVA HYPERTROPHY; GINGIVITIS; HEPATITIS B; HEREDITY; HIRSUTISM; HONG KONG; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION; INJECTION SITE REACTION; KIDNEY BIOPSY; KIDNEY DISEASE; LEUKOPENIA; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW DRUG DOSE; LOW FAT DIET; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MORTALITY; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; PREGNANCY; PREVALENCE; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SMOKING CESSATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; UTERINE CERVIX CARCINOMA IN SITU;

EID: 36248933756     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.6.925     Document Type: Review

References (100)

1. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract. Ret. Clin. Rheumatol. 16, 847-858 (2002).
2. Mok CC, Lau CS. Lupus in Hong Kong Chinese. Lupus 12, 717-722 (2003).
3. Mok CC, Mak A, Chu WP, To CH, Wong SN. Long term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine (Baltimore) 84, 218-224 (2005).
4. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 52, 2774-2782 (2005).
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J. Rhematol. 22, 1259-1264 (1995).
6. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J. Rheumatol. 24, 1061-1065 (1997).
7. Cervera R, Khamashta MA, Font J et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003).
8. Mok CC, Lee KW, Ho CTK, Lau CS, Wang RWS. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39, 399-406 (2000).
9. Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J. Rheumatol. 27, 1884-1891 (2000).
10. Gourley MF, Austin HA 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125, 549-557 (1996).
11. Petri M. Infection in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 24, 423-456 (1998).
12. Mok CC, Ho CTK, Chan KW, Lau CS, Wang RWS. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 46, 1003-1013 (2002).
13. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934-3940 (2004).
14. Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med. 119, 355 e25-e33 (2006).
15. Jayne D, Rasmussen N, Andrassy K et al; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003).
16. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J. Rheumatol. 27, 1681-1685 (2000).
17. Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am. J. Kidney Dis. 40, 447-457 (2002).
18. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 14, 856-858 (2005).
19. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br. J. Dermatol. 147, 174-178 (2002).
20. Mok CC, Mak A, To CH. Mycophenolate mofetil for lupus-related myelopathy. Ann. Rheum. Dis. 65, 971-973 (2006).
21. Mok CC. Mycophenolate mofetil for nonrenal manifestations of systemic lupus erythematosus: a systematic review. Scand. J. Rheumatol. (in press).
22. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. 31, 213-217 (1998).
23. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. 32, 318-322 (1998).
24. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol. 28, 2103-2108 (2001).
25. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol. 10, 833-839 (1999).
26. Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44, 1317-1321 (2005).
27. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 43, 377-380 (2004).
28. Chan TM, Li PK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156-1162 (2000).
29. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10, 504-510 (2005).
30. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005).
31. Contreras G, Pardo V, Ledercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
32. Tam LS, Li EK, Leung CB et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 91, 573-580 (1998).
33. Tam LS, Li EK, Szeto CC et al. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus 10, 827-829 (2001).
34. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9, 241-251 (2000).
35. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol. 62, 49-53 (2004).
36. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 68, 813-817 (2005).
37. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10, 480-483 (2001).
38. Petera P, Mander B, Manger K et al. A pilot study of leflunomide in systemic lupus erythematosus. Arthritis Rheum. 48, S241 (2001).
39. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13, 601-604 (2004).
40. Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann. Rheum. Dis. 64, 153-155(2005).
41. Goeb V, Berthelot JM, Joly P et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 44, 823-824 (2005).
42. Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 37, 1305-1310 (1994).
43. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a doubleblind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 38, 1826-1831 (1995).
44. Petri MA, Lahita RG, Van Vollenhoven RF et al; for the GL701 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46, 1820-1829 (2002).
45. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2924-2927 (2002).
46. Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50, 2858-2868 (2004).
47. Boumpas DT, Tassiulas IO, Fleisher TA et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol. 52, 67-75 (1999).
48. Davis JC Jr, Austin H 3rd, Boumpas D et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum. 41, 335-343 (1998).
49. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542-1545 (2005).
50. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 52, 3168-3174 (2005).
51. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913-920 (2005).
52. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. 33, 423-427 (2004).
53. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8, R83 (2006).
54. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
55. Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin. Nephrol. 64, 73-77 (2005).
56. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab, in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr. Nephrol. 20, 811-813 (2005).
57. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
58. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459 (2003).
59. Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk. Lymphoma 45, 627-629 (2004).
60. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99, 3256-3262 (2002).
61. Ocrelizumab. Roche Investigator's Brochure (2007).
62. Kaufmann J, Wegener WA, Horak ID et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum. 49 (2004) (Abstract 1127).
63. Furie R, Stohl W, Ginzler E et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double doseescalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum. 48 (2003) (Abstract 922).
64. Wallace DJ, Lisse J, Stohl W et al.; LBSL02 Study Group. Presented at: American College of Rheumatology meeting, Washington, DC, USA. 10-16 November, 2006 (Abstract 2012).
65. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28, 257-265 (2001).
66. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48, 442-454 (2003).
67. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227 (1994).
68. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-2916 (2001).
69. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
70. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159, 3104-3108 (1997).
71. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D, Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 28, 95-101 (2001).
72. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 3251-3258 (2002).
73. Boumpas DT, Furie R, Manzi S et al; BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003).
74. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179, 305-310 (1994).
75. Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43, 1790-1800 (2000).
76. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. 19, 859-878 (2005).
77. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50, 3161-3169 (2004).
78. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147, 117-123 (1991).
79. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/ NZW F1 mice. J. Clin. Invest. 94, 585-591 (1994).
80. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol. 112, 397-402 (1998).
81. Nishimoto N, Miyasaka N, Yamamoto K et al. Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, a humanized anti-IL6 receptor antibody, in active rheumatoid arthritis patients. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10-16 November, 2006 (Abstract 945).
82. Illei GG, Yarboro C, Shirota Y et al. Tocilizumab (humanized anti-IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10-16 November, 2006 (Abstract L20).
83. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl Acad. Sci. USA 93, 8563-8568 (1996).
84. Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13, 328-34 (2004).
85. Sthoeger ZM, Dayan M, Tcherniack A et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin. Exp. Immunol. 131, 385-392 (2003).
86. Luger D, Dayan M, Zinger H et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24, 579-590 (2004).
87. Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121, 248-257 (2007).
88. Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract. Res. Clin. Rheumatol. 19, 839-858 (2005).
89. Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13, 168-176 (2004).
90. Brodsky RA, Petri M, Smith BD et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med. 129, 1031-1035 (1998).
91. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 48, 166-173 (2003).
92. Petri M, Brodsky R, Jones R, Gladstone D, Fillius M, Magder L. High-dose cyclophosphamide vs monthly (NIH) cyclophosphamide: final results. Presented at: American College of Rheumatology Meeting, Washington, DC, USA, 10-16 November, 2006 (Abstract 1038).
93. Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831-837 (1998).
94. Somers EC, Marder W, Christman GM et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52, 2761-2767 (2005).
95. Ramsey-Goldman R, Dunn JE, Huang CF et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 42, 882-890 (1999).
96. Yee CS, Crabtree N, Skan J et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 111-113 (2005).
97. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106-112 (2005).
98. Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33, 293-300 (2003).
99. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287, 847-857 (2002).
100. Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum. 52, 3997-4002 (2005).